Ataraxis AI Launches Ataraxis Breast CTX, the First Predictive AI Test Estimating Individualized Chemotherapy Benefit in Breast Cancer
recent articles
NEW YORK--(BUSINESS WIRE)--Ataraxis AI, a frontier artificial intelligence (AI) research lab developing AI-powered tools for oncology, today announced Ataraxis™ Breast CTX, a new predictive capability within its Ataraxis Breast...
Lunit, CellCarta: Partnership combines Lunit's platform-agnostic AI pathology algorithms with CellCarta's global CDx development and laboratory execution to help biopharma teams de-risk assets and accelerate evidence generation and CDx launch...
Lumea: IMS Viewer+ (FDA-cleared and CE-marked under IVDR) now seamlessly incorporates Cleo Skin, Primaa’s AI solution, into dermpaths' digital workflows. LEHI, UT, UNITED STATES, March 24, 2026 /EINPresswire.com/ -- Lumea, the U.S. leader in...
HNL Lab Medicine to integrate Ibex’s AI-powered solution for prostate cancer, building on its existing digital pathology foundation to support high-precision diagnostics BOSTON & ALLENTOWN, Pa.--(BUSINESS WIRE)--Ibex...
VISTA, Calif., March 23, 2026 /PRNewswire/ -- Leica Biosystems, a Danaher Company and a global leader in anatomic pathology solutions, continues to enhance digital pathology workflows with the US launch of the Aperio GT EliteTM scanner,...
Discovery Life Sciences and Mindpeak: New alliance takes aim at inconsistent biomarker interpretation across pathologists, a persistent challenge in drug development HUNTSVILLE, Ala. and HAMBURG, Germany, March 24, 2026 /PRNewswire/ --...
